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NeuroprotectionNucleotides activating P2Y13 receptors display neuroprotective actions against different apoptotic stimuli in cer-
ebellar granule neurons. In the present study, P2Y13 neuroprotection was analyzed in conditions of genotoxic
stress. Exposure to cisplatin and UV radiation induced caspase-3-dependent apoptotic cell death, and p38
MAPK signaling de-regulation. Pre-treatment with P2Y13 nucleotide agonist, 2methyl-thio-ADP (2MeSADP),
restored granule neuron survival and prevented p38 long-lasting activation induced by cytotoxic treatments. Mi-
croarray gene expression analysis in 2MeSADP-stimulated cells revealed over-representation of genes related to
protein phosphatase activity. Among them, dual-speciﬁcity phosphatase-2, DUSP2, was validated as a transcrip-
tional target for P2Y13 receptors by QPCR. This effect could explain 2MeSADP ability to dephosphorylate a DUSP2
substrate, p38, reestablishing the inactive form. In addition, cisplatin-induced p38 sustained activation correlated
perfectlywith progressive reduction inDUSP2 expression. In conclusion, P2Y13 receptors regulate DUSP2 expres-
sion and contribute to p38 signaling homeostasis and survival in granule neurons.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Mitogen-activated protein kinases (MAPKs) regulate a great variety
of physiological and pathological processes at the central nervous
system including survival/apoptosis, proliferation or differentiation.
Among them, the extracellular signal-regulated kinases (ERK) are main
targets of growth factors and neurotrophins [1–3]. In general, ERK1,2
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y.apoptotic stimuli [4,5]. Concerning the stress related kinases, p38 and
JNK, theymainly function as cell deathmediators in response to environ-
mental, inﬂammatory and danger stimuli [6,7]. Despite this general rule
for MAPKs, their real contribution to neural function is not yet totally
clariﬁed. In this respect, long-lasting activation of MAPKs, including
ERK1/2, is associated to cell death under damaging conditions, such as
cytotoxicity, hypoxia/ischemia, oxidative and genotoxic stress [8,9].
Therefore, it is becoming clear that cell fate as a result ofMAPK activation
seems to be strongly dependent on different factors, such as the cellular
environment, type of stimuli and signal duration.
MAPK pathways entail several phosphorylating events that work in
cascade. They are tightly regulated at multiple levels, and among them,
modulation of protein phosphatase activity plays a key role in the regu-
lation of both duration and magnitude of MAP kinase signaling [10,11].
Different families of protein phosphatases, serine-threonine (PSPs) and
tyrosine phosphatase proteins (PTPs and DUSPs), have been identiﬁed
to operate coordinately to inactivate MAPK signaling, acting through
both positive and negative feedback regulatory mechanisms. Among
them, dual-speciﬁcity protein phosphatases, DUSPs, exhibit activity to-
wards both Thr and Tyr residues. Some members of this family belong
to the group of MAPK phosphatases or MKPs, and are emerging as
major mediators of the inactivation of sustained MAPK signaling in-
duced by growth factors. Both constitutive and inducible DUSPs can co-
exist in a cellular model and are transcriptionally regulated by growth
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[10,12,13]. They exhibit different substrate selectivity towards a partic-
ular MAPK protein, and their expression or activation is normally
dependent on the same MAP kinase under regulation [14,15]. Among
the most representative ones, DUSP1 and DUSP2 belong to the group
of nuclear inducible phosphatases with broad speciﬁcity for ERK1/2
and stress kinases, JNK and p38. In addition, DUSP6 belongs to the
group of cytoplasmic and constitutive phosphatases more selective for
ERK1/2. However, not many pharmacological tools are available to
properly characterize protein phosphatases.
Extracellular nucleotides play relevant roles at the nervous system
through their coupling to MAP kinase signaling [16,17]. They activate
two major families of nucleotide receptors, both ionotropic (P2X) and
metabotropic (P2Y) (see recent reviews) [18,19]. In recent works, we
described neuroprotective actions displayed by P2Y13 and P2X7 recep-
tors in cerebellar granule neurons (CGNs). The survival promoting effect
against glutamate excitotoxicity proved to be dependent on the activa-
tion of the ERK1/2 target that is the CREB transcription factor. P2Y13 and
P2X7 receptors were differently coupled to ERK1/2 activation through
PI3K and CaMKII-dependent pathways, respectively [20]. In addition,
P2Y13 receptors prevented oxidative stress-mediated cell death through
the up-regulation of the cyto-protective protein heme oxigenase-1
(HO-1), which is a transcriptional product of the master antioxidant
regulator Nrf-2 transcription factor [21].
The aim of the present study was to deepen into the meaning of
P2Y13 receptors neuroprotective actions in granule neurons. Their role
was investigated in conditions of genotoxic stress induced by exposure
to UV radiation and cisplatin, a drug commonly used in chemotherapy
with important neurotoxic side effects [22]. We described the impair-
ment of MAP kinase signaling, especially at the level of p38 phosphory-
lated form accumulation, in response to cytotoxic treatments. This effect
correlated with loss of function of a speciﬁc type of dual-speciﬁcity pro-
tein phosphatase, DUSP2, selective for p38. In addition, activation of
P2Y13 receptor with 2MeSADP nucleotide agonist was sufﬁcient to pre-
vent p38 over-activation as well as to restore basal DUSP2 expression.
Finally, P2Y13 activation induced by 2MeSADP contributed to promote
neuronal survival against those cytotoxic treatments. Both, the induc-
tion of protein phosphatase and the neuroprotective effect were depen-
dent on PI3K/ERK-dependent signaling triggered by P2Y13 receptors in
granule neurons [20].
2. Materials and methods
2.1. Antibodies and materials
Nucleotide receptor agonists and antagonists, and transducing
inhibitors, 2MeSADP and ortho-vanadate, were purchased from Sigma
Aldrich (St Louis, USA), MRS-2211 from Tocris Bioscience (Essex, UK),
and Wortmannin and U-0126, from Calbiochem Co. (San Diego, USA).
Speciﬁc antibodies for phosphor-ERK1/2 (Tyr204), ERK2 were from
mouse, and for DUSP2 were from goat, and purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies speciﬁc for
GAPDH, 17 kDa-Caspase-3 fragment, phosphor-p38, phosphor-JNK
and p38were from rabbit and purchased from Cell Signalling Technolo-
gy (Beverly, MA, USA). Secondary horseradish peroxidase-conjugated
antibodies were from Santa Cruz Biotechnology (anti-mouse), and
Dako (Denmark) (anti-rabbit, anti-goat) and Synaptic Systems (donkey
anti-rabbit IgG Cy3-conjugated). All other reagents not speciﬁed were
routinely supplied by Sigma, Merck (Darmstadt, Germany) or Roche
Diagnostics SL (Barcelona, Spain).
2.2. Cell culture and treatment conditions
All experiments carried out at the Universidad Complutense de
Madrid followed the guidelines of the International Council for Laborato-
ry Animal Science (ICLAS). Cerebellar cultures were performedaccording to the procedure described by Pons et al. with somemodiﬁca-
tions [23]. Cerebella fromWistar rat pups (P7)were aseptically removed,
and submitted to digestion with papain 100 U/ml (Worthington, Lake
Wood, NJ) (previously activated in EBSS buffer containing 5 mM L-Cys
and 2 mM EDTA), in the presence of 100 U/ml of DNAse (Worthington,
Lake Wood, NJ), 1 mM CaCl2 and 1 mMMgCl2. The obtained cells were
resuspended in neurobasal medium supplemented with B-27 (GIBCO,
BRL, Paisley, Renfrewshire, UK) containing 21mMKCl, 2 mM glutamine,
and antibiotics, 100 U/ml penicillin, 0.1 mg/ml streptomycin and
0.25 μg/ml amphotericin B (Sigma Aldrich, St Louis, USA), and plated
onto glass coverslips or plastic Petri dishes (60 and 35 mm) (Falcon
Becton Dickinson Labware, Franklin Lakes, USA) precoated with
0.1 mg/ml poly-L-lysine (Biochrom, AG, Berlin) at a density of
200,000 cells/cm2. They were maintained in a humidiﬁed incubator at
37 °C in 5% CO2. AraC (10 μM) was added to avoid the proliferation of
glial cells.
Cultured cerebellar granule neurons were used at 8–10 DIV (days
in vitro), the stimulation of cells with the nucleotide agonists or other
agents was carried out adding the corresponding compounds to cells
maintained in complete culture media. These stimulations were done
at speciﬁed times before the addition of the cytotoxic drug, cisplatin at
concentrations of 20 or 40 μg/ml. The exposition to UV radiation was
performed for 2 min under transilluminator lamp (32 J/cm2), after
that, cells were maintained in the incubator until the times required.
2.3. Western blot experiments
In phosphorylation assays of MAPK proteins, cell extracts or lysates
were obtained at different incubation periods. Stimulation was stopped
by the addition of lysis buffer (20 mM MOPS, 50 mM NaF, 40 mM
β-glycerophosphate, 1 mM sodium orthovanadate, 5 mM EDTA, 2 mM
EGTA, 0.5% Triton X-100, pH = 7.2, 1 mM PMSF and protease inhibitor
cocktail (Complete, Roche)). Protein determination of the cell ex-
tracts was performed and thenmixedwith sample buffer 4× (50% glyc-
erol, 125 mM Tris pH 6.8, 4% SDS, 1% bromophenol blue, 5%
β-mercaptoethanol, 4.5% H2O). The samples were heated to 99 °C and
aliquots (25 μg) were subjected to sodium dodecyl sulfate (SDS) gel
electrophoresis (25 mM Tris, 200 mM glycine, 0.1% SDS, pH = 8.3)
using 12% acrylamide gels. Immunotransference was performed in
PVDF membranes (Amersham Biosciences Europe GmbH, Barcelona,
Spain) (25 mM Tris, 192 mM glycine, 20% methanol). The TBS buffer
(100 mM NaCl, 10 mM Tris–HCl, pH 7.5) containing 1% (v/v) Tween-
20 and 5%BSAwas employed as blockingmediumand in subsequent in-
cubations with the antibodies. Incubation with the antibodies was per-
formed at the following dilutions: 1:1000 for phosphor-ERK1/2, total
ERK (Santa Cruz), total p38, GAPDH, and caspase-3 (Cell Signalling),
and 1:500 for phosphor-p38, phosphor-JNK (Cell Signalling) and
DUSP2 (Santa Cruz). Primary antibodies were detected with horserad-
ish peroxidase-conjugated antibodies, 1:4000 for anti-mouse (Santa
Cruz) and anti-rabbit (Dako), and 1:2000 for anti-goat (Santa Cruz) vi-
sualized by the ECL method (kit Super Signal substrate Western Blot-
ting, from Amersham Biosciences Europe GmbH, Barcelona, Spain).
The chemiluminescence images were quantiﬁed by densitometry
employing the Fluo-S Imager of Bio-Rad (Munich, Germany).
2.4. Microarray analysis
RNA was collected from cells treated with 1 μM 2MeSADP for 2 h.
Sampleswere hybridizedwith a chip of genomic expression Agilent, ca-
pable of quantifying the expression of 28,000 rat genes. 4 replicates of
each condition (Control or 2MeSADP) were performed and analyzed.
The resultant expression datawas normalized following themethod de-
scribed by Bolstad et al. [24] and implemented into the analysis package
affy [25] for the statistic environment R (GNU project http://www.r-
project.org/).
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trol and treated samples. T-test following subsequent correction by
Bonferroni method was applied to the average expression of each
gene within the two groups. To achieve that, the analysis platform for
microarrays GEPAS [26] was employed alongwith the statistic environ-
ment R.
Functional analysis of the genes, sorted by their degree of differential
expression, was performed employing the bioinformatics software
Fatiscan [27], currently implemented into the online platform
Babelomics [28]. This method allows, by the employing of a segmenta-
tion test, to detect functional groups of genes that additionally exhibit
expression differences. A short partition size of 50 genes, a two-tails
Fisher test and a signiﬁcant degree of signiﬁcance of P b 0.05 was used
in this analysis.2.5. Real time RT-QPCR
Total RNA was isolated from granule cells after the indicated treat-
ments for different periods of time with the RNeasy Qiagen kit, and
1 μg DNAse-treated RNA (Turbo-DNA free, Ambion) was used for ﬁrst
strand cDNA synthesis, according to the manufacturer's protocolGAPDH
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Fig. 1. Activation of caspase-3 and MAPK proteins upon cisplatin treatment in granule neurons
cell lysates were collected at different times after treatment. Analysis was carried out by immu
phorylated forms of ERK1/2, p38 and JNK (B), as described in the Materials and methods. The
respect to non-stimulated cells (100% basal), and were obtained by normalization of densitom
periments performed from different cultures (n = 10). Data were statistically signiﬁcant at *P b
compared to basal (open bars, in the absence stimulation).(TaqMan Reverse Transcript Reagents, Applied Biosystems kit). Quanti-
tative real time PCR was performed using Applied Biosystems Step One
Plus and speciﬁc primer and probe setswere purchased from Roche Ap-
plied Science (Universal ProbeLibrary Probes labeled with FAM), being
the forward and reverse primer pairs: AGGCTATCGGCTTCATTGAC/
TCGATGGCTCTGAATCAGGT for dusp2, and CCCCTCTGGAAAGCTGTG/
GGATGCAGGGATGATGTTCT for gapdh. The ampliﬁcation was per-
formed using LuminoCt® Qpcr Ready Mix™ (Sigma) and run for 20 cy-
cles (94 °C 30 s, 60 °C 30 s). Relative quantiﬁcations were normalized
with respect to the gapdh endogenous control data, and results are
expressed as increments in expression with respect to control condi-
tions (in the absence of any stimulation).2.6. Immunocytochemistry experiments
Cells plated onto glass coverslips were ﬁxed with PFA (4%, w/v) for
15 min and permeabilized with Triton X-100 (0.1%, v/v) in PBS/BSA
(3%, w/v) containing 5% of donkey serum for 1 h at 37 °C. The primary
antibody, rabbit anti-phosphor-p38 (1:100) was diluted in PBS/BSA
and applied overnight at 4 °C. The secondary antibody, donkey anti-
rabbit IgG Cy3-conjugated (1:400), was incubated in PBS/BSA for 1 hBasal 2h 6h 16h 24h
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. Granule neurons in complete culture media were exposed to 20 μg/ml cisplatin and total
noblot using antibodies against the 17 kDa active fragment of caspase-3 (A) and the phos-
blots correspond to representative experiments. Histograms represent the increase with
etric values of phosphoproteins with respect to GAPDH. Values are the means ± SD of ex-
0.05, **P b 0.01, ***P b 0.001, when the effects after cisplatin treatment (solid bars) were
1889V. Morente et al. / Biochimica et Biophysica Acta 1843 (2014) 1886–1898at 37 °C. Finally, cellswerewashed three times and incubatedwith 1 μM
DAPI to stain nuclei. After twowashes in PBS, covers weremounted fol-
lowing standard procedures (Prolong Anti-Fade). Controls were pre-
pared according to the same protocol by replacing primary antibodies
with the same volume of PBS/BSA solution, and followed by the incuba-
tionwith the secondary antibodies. Confocal imageswere acquiredwith
a TCS SPE microscope from Leica Microsystems (Wetzlar, Germany).
Densitometric analysis of the photographs was performed using ImageJ
and Leica LAS AF Lite software.
2.7. Cell viability assays
Cells were treated for 1–2 h with the nucleotide agonist, 2MeSADP,
in the absence or presence of nucleotide receptor antagonist or trans-
ducing protein inhibitors, before the addition of cisplatin (20 μg/ml),
or the exposure to UV radiation for 2 min. Cell viability was tested
24 h later by the MTT assay that measures mitochondrial function.
After the corresponding treatments, the tetrasodium salt MTT (3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) was
added to the cultures to a ﬁnal concentration of 0.5 mg/ml, and
maintained for 2 h at 37 °C. Then, an equal volume ofMTT solubilizationB        2h       6h       16h       2h        6h      16h
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Fig. 2. Effect of P2Y13 nucleotide agonist on cisplatin-induced p38 sustained activation in cereb
1 μM2MeSADP for 2 h, before the addition of 20 μg/ml of cisplatin, and then phosphorylated p3
neurons were incubated in the presence or absence of the P2Y13 antagonist 10 μMMRS-2211 fo
nucleotide agonist. 2 h later cisplatin was added and cell lysates were collected at 6 h. The blots
with respect to non-stimulated cells (100% basal), and were obtained by normalization of dens
experiments performed from different cultures (n = 9). Data were statistically signiﬁcant at *P
basal (open bars, in the absence stimulation), and at #P b 0.05, ##P b 0.01, ###P b 0.001, whe
(B) datawere statistically signiﬁcant at §§§P b 0.001when the treatmentswere compared in the
experimental design.solution (10% Triton X-100 plus 0.1 N HCl in anhydrous isopropanol)
was added, following a brief incubation of 30 min at room temperature
with orbital shaking. The sampleswere collected andmeasured spectro-
photometrically at 570 nm. Values were normalized in respect to that
obtained from untreated cells, considered as 100% survival.
2.8. Statistical analysis
Data are represented asmeans±SD of at least 3 independent exper-
iments obtained from different cultures. Comparison between different
treatments and controls was carried out using Dunnett's test, and com-
parison between different samples was done by applying Tukey's test.
3. Results
3.1. MAPK signaling is deregulated in granule neurons upon
cisplatin exposure
MAPK signaling cascades result deregulated in response to several
toxic insults that induce genotoxic stress. We studied these alterations
in granule neurons exposed to the genotoxic agent, cisplatin. ExposureCis
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Changes were most signiﬁcant for p38, which resulted an increase of
about 8–10 times over basal levels, whereas moderate levels of around
2–3 times were obtained for ERK1/2 protein phosphorylation (Fig. 1B).
In contrast, phosphorylated levels were barely affected for the other
stress-related MAP kinase, JNK (Fig. 1B).
3.2. P2Y13 nucleotide receptor agonist, 2MeSADP, prevents
cisplatin-induced p38 sustained phosphorylation
The effect of P2Y13 nucleotide receptor activation under cisplatin
treatment was then analyzed with respect to p38 signaling over-
activation. According to that previously described, the nucleotide agonist
2MeSADP was employed to activate P2Y13 receptors expressed in gran-
ule cells [20,29,30]. Treatment with 1 μM 2MeSADP for 2 h prior to cis-
platin exposure was sufﬁcient to reduce long-lasting levels of p38
phosphorylation in a signiﬁcant percentage, which accounted for
50–60% decrease at different times of treatment with the cytotoxic
drug (Fig. 2A). Several incubation times with the nucleotide agonist
were tested, and the dephosphorylation effect began to be evident
from the ﬁrst hour of treatment, without apparent improvements if it
was prolonged for 4 h. Therefore, 2 h pre-incubation time was chosen
to get the most signiﬁcant effect, ﬁtting perfectly to the previous work
in which 2MeSADP mediated neuroprotective effects were observed at
this incubation period [20]. Under these conditions, pre-treatment
with P2Y13 antagonist, MRS-2211, totally abolished the ability of
2MeSADP to decrease p38 phosphorylation levels, elevated as a conse-
quence of cisplatin treatment, conﬁrming the speciﬁcity of the effect
(Fig. 2B).
These results suggested that themechanism of action of P2Y13 nucle-
otide agonist preventing p38 MAPK over-activation in granule neurons
could require a protein phosphatase activity. This was supported by
using orthovanadate, a general inhibitor of protein tyrosine phospha-
tases. Pretreatment of granule neuronswith this inhibitor did not induce
a signiﬁcant change in basal levels of phosphorylated p38 proteins, al-
though slightly increased when obtained in the presence of cisplatin.
Noticeably, it prevented the ability of 2MeSADP to reduce sustained
p38 phosphorylation (Fig. 2B).
MAPK signaling elicited by P2Y13 receptor activation was also ana-
lyzed as a function of time in granule neurons. 2MeSADP was coupled
to ERK1/2 phosphorylation in a transient pattern, reaching a peak at
30 min of exposition time and slowly returning towards baseline levels
at 1–2 h (Supp. Fig. 1A). In contrast, no changes in p38 phosphorylation
levels were detected upon treatment with 2MeSADP, indicating that
P2Y13 receptors are not coupled to p38 activation in this cellular
model (Supp. Fig. 1B).Table 1
Functional enrichment analysis of rat genes in control and 2MeSADP treated cultures of cerebe
Gene Ontology term GO term #genes
(UpList)
#genes
(OutList
Protein dephosphorylation GO:0006470 98 7
Cellular protein modiﬁcation process GO:0006464 767 87
Dephosphorylation GO:0016311 116 9
Post-translational protein modiﬁcation GO:0043687 673 81
Phosphate-containing compound metabolic process GO:0006796 686 79
Enzyme binding GO:0019899 237 64
Hydrolase activity, acting on ester bonds GO:0016788 331 39
Phosphatase activity GO:0016791 150 14
Phosphoprotein phosphatase activity GO:0004721 104 6
Protein kinase binding GO:0019901 105 3
Kinase binding GO:0019900 119 6
Genes present in several signiﬁcantly up-regulated functional Gene Ontology (GO) categories.
analyze the complete list of rat genes ranked according to their differential expression (T-test
to the number of genes in a functional category that exhibit higher expression differences tha
regulated functions under 2MeSADP treatment, including previously described Dusp2 molecu
complete list of genes in the up-regulated functional categories is provided as Supplementary3.3. P2Y13 nucleotide agonist, 2MeSADP, prevents phosphorylated p38
nuclear accumulation induced by cisplatin treatment
Considering that several danger stimuli evoke translocation of active
p38 form from cytoplasm to the nucleus [31], p38 subcellular distribu-
tionwas analyzed by immunocytochemistry in granule neurons follow-
ing cisplatin exposure. In accordance to that described in neural models,
basal phosphorylated p38 levels were very low and uniformly distribut-
ed throughout the nucleus and cytoplasm in non-stimulated cells,
showing slight decreases upon stimulation with 2MeSADP for 2 h.
After 4 h cisplatin treatment, an intense staining pattern was observed
for phosphorylated p38 at the nucleus co-localizing perfectly with nu-
clear binding dye, DAPI. As expected, 2 h pre-treatment with 2MeSADP
exhibited a robust effect reversing cisplatin-induced p38 nuclear accu-
mulation, and phosphor-p38 levels returned to basal levels (Fig. 3). In
addition, 2MeSADPwas able to prevent increase in apoptotic nuclei ob-
served after cisplatin treatment.
3.4. P2Y13 nucleotide agonist, 2MeSADP, prevents UV-induced p38
sustained activation
UV radiation is another approach that was analyzed to induce
genotoxic stress conditions. Granule cells were exposed to UV radiation,
and then cell extracts were collected at different times. In comparison
to cisplatin treatment, UV light resulted to be a more potent apoptotic
stimulus, as caspase-3 activation was reached at earlier incubation time
of 6 h (Fig. 4A). In addition, UV radiation caused similar effects to cisplatin
treatment in terms of long-lastingMAPK protein phosphorylation. Again,
major increases were observed at the level of p38 protein that reached
10-fold as early as 30 min after UV exposure and decreasing only at
24 h. Minor 2-fold increments were obtained for both ERK1/2 and JNK
proteins (Fig. 4A and B). As expected, pre-treatmentwith 1 μM2MeSADP
for 2 h prior to UV exposure, was able to decrease signiﬁcantly p38 phos-
phorylated levels at all times tested, in a similar manner to that observed
with cisplatin (Fig. 4B). These results indicate that p38 activation appears
to play a central role in granule neurons submitted to genotoxic stimuli,
and that P2Y13 receptors seem to operate through similar intracellular
mechanisms in restoring basal p38 MAPK phosphorylation.
3.5. Microarray gene expression analysis in granule neurons stimulated
with 2MeSADP
The above results provide evidence of P2Y13 involvement in the reg-
ulation of protein phosphatase activity, restoring basal p38 phosphory-
lation after exposure to cisplatin or UV light. Different kinds of tyrosine
protein phosphatases exhibiting substrate speciﬁcity towards MAPKsllar granule neurons.
)
Genes present in the up-regulated list Adj. P value
Dusp13, Dusp9, Ptprj, Sox10, Sox5, Ptpn18, Dusp2, Ptpn6, (…) 1.66E−002
Bcam, Prkci, Sox5, Thy1, Arrb1, II2, Ptpn18, Dusp2, Stk17b (…) 9.84E−009
Dusp13, Dusp9, Ets1, Ptprj, Pnkp, Dusp2, Ptpn6, (…) 1. 32E−002
Dusp2, Il1b, Ripk3, Dusp13,Dusp9, Arrb1, II2, Ptpn18, (…) 1. 00E−006
Dusp2, Sox10, Kalrn, Bard1, Bcam, Prkci, Sox5, Thy1, Arrb1, (…) 1.14E−007
Thy1, Dusp2, Plce1, Serpine1, Akap14, Pawr, Tgfbr2, Gck, Insr, (…) 1.12E−003
Dusp13, Dusp2, Plcb3, Dusp9, Aste1, Pola1, Ets1, Aspa, Usp16, (…) 1. 84E−003
Dusp13, Dusp9, Ets1, Ptprj, Sox10, Sox5, Pnkp, Dusp2, Ppap2, (…) 1. 98E−002
Dusp13, Dusp9, Ets1, Ptprj, Sox10, Sox5, Dusp2, Ptpn, (…) 5.84E−003
Akap14, Tgfbr2, Insr, Ets1, Cdk5rap2, Sox10, Dusp2, Prkab2, (…) 1. 00E−004
Akap14, Tgfbr2, Insr, Ets1, Cdk5rap2, Sox10, Dusp2, Prkab2, (…) 7.69E−004
The software FatiScan [27], as implemented in the babelomics web tool [27], was used to
) between control and 2MeSADP treated cultures. For each functional term, UpList refers
n the rest in the same category (OutList). Note that Dusp2 appears associated to the up-
lar activities such as phosphatase activity and phosphoprotein phosphatase activity. The
ﬁle 1.
1893V. Morente et al. / Biochimica et Biophysica Acta 1843 (2014) 1886–1898were among the possible candidates, including PTPs and DUSP families.
In order to screen for a speciﬁc phosphatase that could explain the
effect obtained with P2Y13 agonist, we performed studies of gene ex-
pression by microarray analysis in granule neurons treated with
2MeSADP for 2 h, the incubation period in which 2MeSADP was more
potent at inducing p38 dephosphorylation and exhibiting neuroprotec-
tive properties.
Gene expression analysis did not show any signiﬁcant differences in
2MeSADP stimulated cells concerning up- or down-regulation of speciﬁc
genes when they were analyzed individually. However, functional anal-
ysis revealed over-represented clusters of genes associated with speciﬁc0
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The occurrence of several protein phosphatases in every list of
grouped genes that belong to the family of dual speciﬁcity phospha-
tases, which were DUSP13, DUSP9 and DUSP2 was noteworthy. The
last two are also termed “classical DUSPs” orMKPs, because they exhibit
substrate speciﬁcity for MAP kinases. Meanwhile, DUSP13 is classiﬁed
as “atypical DUSP”, whose substrate and physiological function are still
unknown [13]. Taking into account that DUSP13 was not related to
MAPK function, it was dismissed for further analysis. Between classical
DUSPs, DUSP9 belonged to the group of cytoplasmic constitutive phos-
phatases selective for ERK1/2, and it was excluded for our studies. Con-
sequently, we focused our interest on DUSP2 inducible phosphatase,
also termed as PAC-1, as a good candidate for mediating p38 dephos-
phorylation triggered by 2MeSADP in granule cells. It is to emphasize
that this enzyme displays substrate selectivity for both p38 and ERK1/
2 MAPKs, and exhibits nuclear localization [12].
3.6. DUSP2 protein phosphatase expression is induced by P2Y13 receptor
activation in granule neurons
Validation of data obtained in microarray analysis was undertaken
by examining DUSP2 expression in cells stimulated with 2MeSADP nu-
cleotide agonist. In accordance with the nature of dusp2 as IEG, dusp2
mRNA levels measured by real-time Q-PCR resulted to be increased
2-fold as early as 30 min incubation period with 2MeSADP, and
remained elevated over basal until 1–2 h (Fig. 5A). As it can be observed
in the ﬁgure, the exposure to the cytotoxic drug decreased dusp2mRNA
levels in a time-dependent manner. This effect was counteracted when
cells were pre-treated with the nucleotide agonist 2MeSADP (Fig. 5A).
Accordingly, DUSP2 expression at the protein level was also in-
creased by stimulation with 2MeSADP, which was detectable as early
as 30min and reachedmaximum around 2 h (Fig. 5B). This was demon-
strated to be a P2Y13 receptor mediated effect, as was abolished upon
treatment with the antagonist MRS-2211. In addition, 2MeSADP-
induced DUSP2 expression was lost in the presence of the inhibitors,
U-0126 and wortmannin, selective for MEK-1 (ERK1/2 upstream ki-
nase) and PI3K, respectively (Fig. 5C). Therefore, P2Y13 receptor activa-
tion was coupled to DUSP2 expression through the ERK1/2-canonical
signaling described for this receptor in granule neurons, which was de-
pendent on PI3K activity [20].
These data suggest that DUSP2 constitutes a speciﬁc target for P2Y13
receptor activation, explaining its effects in restoring p38 MAPK signal-
ing in granule neurons under conditions of genotoxic stress.
3.7. Analysis of DUSP2 protein phosphatase expression in granule neurons
exposed to cisplatin and UV light
Subsequent studies were carried out to conﬁrm the correlation be-
tween changes in DUSP2 activity and expression with altered p38
over-activation in granule neurons exposed to cisplatin and UV radia-
tion. To address this goal, DUSP2 expression was analyzed in granule
neurons after exposure to genotoxic stimuli. Cisplatin treatment induced
a clear inverse relationship betweenDUSP2 protein levels and p38 phos-
phorylation over time (Fig. 6), whichwas in agreement with dusp2mes-
senger transcriptional inhibition shown before (Fig. 5A). Cells exhibited
low basal expression of DUSP2, as expected for an inducible protein
phosphatase. However, treatment with cisplatin produced a progressive
decrease in DUSP2 protein, inducing an almost complete loss after 16 h.
This was coincident to maximal increases in phosphorylated p38 levels
up to 8–10-fold within this incubation time. Interestingly, cisplatin
used at a higher dose, 40 μg/ml, led to complete disappearance of
DUSP2 protein beyond 30 min exposure period and to phosphorylated
p38 signal saturation as soon as 2 h (Fig. 6). The same opposite pattern
was observed between DUSP2 protein levels and phosphorylated p38
form after UV treatment, although in this case, DUSP2 expression losswas observed at earlier incubation times of 2 h (Suppl. Fig. 2). These re-
sults indicate that impairment in DUSP2 protein phosphatase expression
could be responsible of p38MAPK signaling deregulation in granule neu-
rons exposed to genotoxic stress.
3.8. Neuroprotection elicited by P2Y13 receptor activation against cisplatin
and UV-induced cell death
Granule cell viability was analyzed in conditions of genotoxic stress
induced by cisplatin and UV light. As described in previous sections,
caspase-3 dependent apoptotic pathway was activated after exposure
to cisplatin (Fig. 1). This corresponded to decrease in cell viability
close to 60% as quantiﬁed by the MTT survival assay. Previous stimula-
tion with 1 μM 2MeSADP for 2 h signiﬁcantly prevented the cytotoxic
effect of the drug maintaining the cell survival up to 80%. 2MeSADP-
mediated neuroprotective effect was completely lost when cells were
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naling transducing inhibitor, U-0126. In addition, when the protein ty-
rosine phosphatase inhibitor, orthovanadate, was tested, cell survival
was severely compromised and 2MeSADPwas no longer able to protect
cells from death (Fig. 7). Similar results were observed when cells were
exposed toUV radiation (Fig. 7). Although this treatment inducedmajor
levels of cell death, 2MeSADP was still able to maintain cell survival,
with the same proﬁle observed with cisplatin. Finally, as expected for
P2Y13 mediated signaling, the use of the speciﬁc inhibitor of p38,
SB202190, had no signiﬁcant effect on the protective effect elicited by
2MeSADP. In addition, it did not protect granule neurons from toxicity
induced by cisplatin and UV light (Supplementary Fig. 3). These data
give evidence that 2MeSADP survival promoting effect was dependent
on ERK1/2 signaling and that intact protein tyrosine phosphatase activ-
ity contributes to granule cell survival.
4. Discussion
The present study describes that P2Y13 nucleotide receptor partici-
pates in the negative feedback regulation of p38 signaling in granuleneurons. This effect is carried out through the activation of DUSP2 phos-
phatase expression, contributing to restoration of MAPK signaling, im-
paired upon conditions of genotoxic stress. This is the ﬁrst study
demonstrating coupling of nucleotide receptor to the expression of
dual-speciﬁcity protein phosphatases in a neuronal cell model. In addi-
tion, this work emphasizes the relevance of protein phosphatase activi-
ty in the maintenance of both basal MAPK signaling and cell survival.
First, it is demonstrated that p38MAPK de-regulation induced by expo-
sure to cisplatin and UV radiation is the consequence of transcriptional
inhibition at the level of dusp2 gene. Second, P2Y13 receptor-induced
neuroprotective effect resulted to be dependent on the recovery of
main levels of phosphatase activity. Both, DUSP2 expression and neuro-
protection, required PI3K/ERK1/2-dependent signaling in cerebellar
granule neurons [20] (a simpliﬁed scheme is represented in Fig. 8).
Our data represent the ﬁrst evidence of dual-speciﬁcity phosphatase
regulation in neuronal cells through extracellular signals different from
growth factors. Indeed, 2MeSADPnucleotide agonist acting on P2Y13 re-
ceptor, increased dusp2mRNA levels that were early detected. This is
consistent with dusp2 being an immediately early inducible gene
(IEG) and belonging to the group of nuclear inducible phosphatases
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Fig. 8. P2Y13 nucleotide receptor participates in the homeostasis of p38 signaling in granule neurons. Impaired inactivation ofMAPK signaling is one of the consequences of DNA damage-
induced neurotoxicity by cisplatin and UV radiation in granule neurons. Accumulation of p38 activated form can be identiﬁed as a response to transcriptional disruption of DUSP2 phos-
phatase elicited by these genotoxic agents. 2MeSADP nucleotide agonist acting through P2Y13 receptor counteracts cisplatin and UV effects, by inducing the expression of dusp2 to deac-
tivate p38 in an ERK1/2-dependentmanner, thereby providing a negative feedback loop to terminate p38 signaling. In addition, 2MeSADP also contributes to rescue granule neurons from
cell death caused by genotoxic stimuli.
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within a timewindow that is coincidentwithmajor effects observed for
2MeSADP at both p38 dephosphorylation and cell survival against cis-
platin treatment. Therefore, both actions of the nucleotide agonist
agree well with recovery of regular DUSP2 activity. It is necessary to
highlight that ERK signaling is required for DUSP2 expression regulation
elicited by P2Y13 receptors, as previously described [32]. Indeed, DUSP
phosphatase expression is usually under the control of MAPK activi-
ty [13,33]. This fact is reported for DUSP1 and DUSP6 submitted to the
regulation of p38 and ERK1/2-dependent transcription factors, respec-
tively [14,34]. Other kind ofmechanisms, however, have been described
in tumoral tissues, in which dusp2 was a product of p53 protein tran-
scriptional activation that would mediate the initiation of the apoptotic
effect and the suppression of tumorigenesis [35].
It is worthmentioning that the impairment of DUSP2 correlates well
with p38 sustained activation in granule neurons. Therefore, its
substrate selectivity towards p38 MAPK protein [12,13] makes DUSP2
a good candidate for the maintenance of p38 signaling in this cellular
model. In addition, ERK1/2 proteins also resulted to a long-term activa-
tion in response to genotoxic stimuli, in a similar way to that reported
for other kinds of toxic conditions, such as glutamate excitotoxicity
and trophic support deprivation in granule cells [36–38]. As deduced
from the microarray gene expression data it cannot be discarded that
other types of protein phosphatases, such as the ERK1/2-speciﬁc
DUSP9 or PTPs, could be also relevant for the regulation ofMAPK signal-
ing in granule neurons stimulated with P2Y13 agonists. Along this
line, P2Y1 nucleotide receptor was reported to regulate MAP kinase
signaling through the activation of PTPs, protein tyrosine phosphatases,
in cortical astrocytes. In thismodel, P2Y1 receptor activationwasprotec-
tive against oxidative stress triggered by H2O2 treatment, through
regulation of PTP activity and promoting the reestablishment of basal
ERK1/2 signaling [39,40]. On the other hand, JNKs seemed not to play
a relevant role in response to genotoxic stress in granule neurons. Thiscould be explained on thebasis that JNKbasal activity is usually elevated
in this model, and no further enhancement was obtained under these
stress conditions. However, in tumoral cell lines, JNKs are strongly acti-
vated after UV exposure[41].
In relation to the outcome of long-term activation of MAPK after
genotoxic stress, it seemed not to be associated to cell death in our ex-
perimental conditions. Cell viability experiments showed that neither
ERK1/2 nor p38 inhibitionwas able to prevent cell death induced by cis-
platin or UV (Fig. 7 and Supplementary Fig. 3). This contrasted to that
described in other cell types in which apoptosis followed ERK1/2 or
p38 sustained activation. In the case of granule neurons, it appears
that other additional factors might contribute to apoptotic effect, as
the nuclear accumulation of ERK1/2 or the activation of ROS [36]. In ad-
dition, other works supported that it was the concomitant activation of
p38 and JNK together with the accumulation of JNK-target c-Jun, which
was required for granule cell death [42,43].
The key role played by DUSP activity as one of themainmechanisms
contributing toMAPKhomeostasis is clariﬁed by the data reported here.
In fact, signaling termination processes are essential to ensure recovery
of basal state, which allow cells to respond to ulterior stimuli and elicit
proper physiological responses. As a signiﬁcant point of control, deﬁ-
ciency in DUSP phosphatase activity appears to highly contribute to
de-regulation of MAP kinase signaling that follows the onset of toxic
or harmful stimuli [44]. Failure in this function can be accomplished
by several mechanisms, such as degradation and transcriptional inhibi-
tion [45]. The later seems to be the mechanism contributing to DUSP2
deﬁciency in tumoral cells exposed to hypoxia and in inﬂammatory
stress conditions [46,47]. Accordingly, a great deal of evidence suggests
that recovery of DUSP activity is essential for cell survival. Indeed,
DUSP1 and DUSP4 overexpression is enough to protect against cell
death induced by UV light and cisplatin exposure in ﬁbroblasts and dif-
ferent cell lines [34,41]. As an example in neuralmodels, DUSP6 expres-
sion was able to rescue cortical neurons from cell death against toxic
1897V. Morente et al. / Biochimica et Biophysica Acta 1843 (2014) 1886–1898glutamate [48] and the same is reported for DUSP1 that maintained cell
viability versus NGF withdrawal in sympathetic neurons [49]. These
data reported for the aforementionedDUSPs support the results obtain-
ed in this study, inwhich restoration of DUSP2 expression contributes to
the survival promoting effect of P2Y13 nucleotide agonist, 2MeSADP, in
granule neurons against genotoxic stimuli. In this regard, it should be
emphasized that other factors besides DUSP2 regulation could be also
participating in 2MeSADP-induced neuroprotection,which are inherent
to P2Y13 receptor coupled signaling. As we demonstrated in previous
work, ERK-dependent CREB activation elicited by P2Y13 receptors
prevented glutamate-induced apoptosis [20]. In addition, P2Y13 activa-
tion was able to rescue granule neurons from oxidative stress injury
through the activation of the Nrf-2/heme oxigenase-1 axis, which was
dependent on P2Y13-mediated GSK3 signaling [21,30].
In conclusion, the present study contributes to demonstrate that
nucleotides are relevant players in negative feedback regulatory mech-
anisms that result critical tomaintainMAP kinase signaling homeostasis
and cell survival. These processes can be then novel targets to be taken
into consideration in conditions related to aging and neurodegenerative
states, in which a great deal of signaling mechanisms result to be
deregulated, MAPK signaling among them. The relevance of neuropro-
tective role played by nucleotides against cisplatin cytotoxicity is
based on the use of this compound in chemotherapy treatments of neu-
roblastoma and other brain tumors, with great limiting side effects re-
lated to neurotoxicity, ototoxicity and peripheral neuropathy [50]. In
addition cisplatin has been reported to induce defects in differentiation
and synaptogenesis events during early development in hippocampal
and cerebellar cell populations [51,52]. Overall these data demonstrates
the pivotal role of P2Y13 to cope with different types of damaging stim-
uli that compromise neural cell viability.
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